• IMA sites
  • IMAJ services
  • IMA journals
  • Follow us
  • Alternate Text Alternate Text
עמוד בית
Mon, 26.02.24

ORIGINAL ARTICLES

IMAJ | volume 25

Journal 8, August 2023
pages: 547-552

Pre- and Post-transcatheter Aortic Valve Replacement (TAVR) Serum Mean Platelet Volume Levels and All-Cause Mortality

1 Department of Cardiology, Tzafon Medical Center, Lower Galilee, Israel 2 Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel 3 Department of Cardiology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel 4 Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel 5 Rappaport Faculty of Medicine, Technion–Institute of Technology, Haifa, Israel

Summary

Background:

Among the most frequent complications following transcatheter aortic valve replacement (TAVR) is hemostasis imbalance that presents either as thromboembolic or bleeding. Deviations in platelet count (PC) and mean platelet volume (MPV) are markers of hemostasis imbalance.

Objectives:

To determine the predictive value of pre- and post-procedural PC and MPV fL 1-year all-cause mortality in patients who underwent TAVR.

Methods:

In this population-based study, we included 236 TAVR patients treated at the Tzafon Medical Center between 1 June 2015 and 31 August 2018. Routine blood samples for serum PC levels and MPV fL were taken just before the TAVR and 24-hour post-TAVR. We used backward regression models to evaluate the predictive value of PC and MPV in all-cause mortality in TAVR patients.

Results:

In this study cohort, MPV levels 24-hour post-TAVR that were greater than the cohort median of 9 fL (interquartile range 8.5–9.8) were the strongest predictor of 1-year mortality (hazard ratio 1.343, 95% confidence interval 1.059–1.703, P-value 0.015). A statistically significant relationship was seen in the unadjusted regression model as well as after the adjustment for clinical variables.

Conclusions

:

Serum MPV levels fL 24-hour post-procedure were found to be meaningful markers in predicting 1-year all-cause mortality in patients after TAVR.

Legal Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal or medical advice on any matter.
The IMA is not responsible for and expressly disclaims liability for damages of any kind arising from the use of or reliance on information contained within the site.
© All rights to information on this site are reserved and are the property of the Israeli Medical Association. Privacy policy

2 Twin Towers, 35 Jabotinsky, POB 4292, Ramat Gan 5251108 Israel